Skip To Main Content
Contact us
|
Help
Home
About
ADR
ADR Archives
Resources
Contact
Flash e-reader
Choose a chapter:
Introduction
Kidney
Pancreas
Liver
Intestine
Heart
Lung
Deceased Organ Donation
Allocation Policies
Appendix
Table Selection
Choose an organ:
All Organs
Kidney
Pancreas
Kidney/Pancreas
Heart
Lung
Heart/Lung
Intestine
Liver
Choose a group:
Choose a characteristic:
Requires
Adobe Acrobat Reader
Table 12.1a
Waiting List Patient Characteristics at End of Year
Lung Waiting List
Active Waitlist Patients, 2000 to 2009
Primary Diagnosis
Year
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
Total
2,485
2,419
2,281
2,315
2,165
1,054
1,033
1,006
1,091
1,198
Emphysema/COPD
821
733
726
715
674
369
370
387
416
422
Cystic Fibrosis
445
431
371
368
340
166
158
144
129
151
Idiopathic Pulmonary Fibrosis
356
380
373
463
396
128
150
158
184
237
Alpha-1-Antitrypsin Deficiency
162
151
140
130
101
74
58
53
54
66
Idiopathic Pulmonary Arterial Hypertension
236
234
181
186
160
74
52
40
39
43
Retransplant/Graft Failure
64
67
63
54
64
25
44
34
33
37
Congenital Disease
57
58
51
34
26
13
15
8
2
4
Other
344
365
376
365
404
205
186
182
234
238
Total (%)
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Emphysema/COPD
33.0%
30.3%
31.8%
30.9%
31.1%
35.0%
35.8%
38.5%
38.1%
35.2%
Cystic Fibrosis
17.9%
17.8%
16.3%
15.9%
15.7%
15.7%
15.3%
14.3%
11.8%
12.6%
Idiopathic Pulmonary Fibrosis
14.3%
15.7%
16.4%
20.0%
18.3%
12.1%
14.5%
15.7%
16.9%
19.8%
Alpha-1-Antitrypsin Deficiency
6.5%
6.2%
6.1%
5.6%
4.7%
7.0%
5.6%
5.3%
4.9%
5.5%
Idiopathic Pulmonary Arterial Hypertension
9.5%
9.7%
7.9%
8.0%
7.4%
7.0%
5.0%
4.0%
3.6%
3.6%
Retransplant/Graft Failure
2.6%
2.8%
2.8%
2.3%
3.0%
2.4%
4.3%
3.4%
3.0%
3.1%
Congenital Disease
2.3%
2.4%
2.2%
1.5%
1.2%
1.2%
1.5%
0.8%
0.2%
0.3%
Other
13.8%
15.1%
16.5%
15.8%
18.7%
19.4%
18.0%
18.1%
21.4%
19.9%
Source: OPTN/SRTR Data as of October 1, 2010.
(%) = Percentages are based on totals including missing and unknown.
(-) = None in category.
Includes patients listed as active status at end of year.